CareLit · DOI-Nachweis · Pneumologie
Effect of baseline FVC on decline in lung function with nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from the INPULSIS® trials
DOI 10.1055/s-0036-1572000
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Pfeifer, M Kolb, T Kimura, S Stowasser, C Hallmann, L Richeldi
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: The two replicate, randomised, placebo-controlled, 52-week INPULSIS® trials assessed the efficacy and safety of nintedanib 150 mg bid in patients with IPF. Patients with FVC ≥50% predicted were included. The primary endpoint, the annual rate of FVC decline, was significantly reduced in the nintedanib group compared with placebo in both trials, consistent with slowing of disease progression. Key secondary…
Zitieren
Zitierempfehlung
M Pfeifer, M Kolb, T Kimura, S Stowasser, C Hallmann, L Richeldi (2016) Effect of baseline FVC on decline in lung function with nintedanib in patients with idiopathic pulmonary fibrosis (IPF): results from the INPULSIS® trials. Pneumologie (02). https://doi.org/10.1055/s-0036-1572000
Mit CareLit weiterarbeiten